PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
|
|
- Brittany Woods
- 5 years ago
- Views:
Transcription
1 PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France
2 LEARNING OBJECTIVES 1. To understand the potential of perioperative treatments 2. To identify patients who should receive perioperative treatment for NSCLC 3. To choose the most appropriate perioperative treatment 4. To know the modalities of delivery for perioperative treatments
3 PERIOPERATIVE TREATMENTS IN NSCLC In EGFR wild-type NSCLC Perioperative chemotherapy Preoperative chemoradiation Perioperative targeted treatments Perioperative immunotherapy Postoperative mediastinal radiotherapy In EGFR mutated NSCLC
4 ADJUVANT CHEMOTHERAPY: SURVIVAL RESULTS 1 (Individual patient data Meta-analysis) Simple non-stratified Kaplan-Meier curves for trials of surgery (S) and chemotherapy (CT) vs. surgery alone and for trials of surgery and chemotherapy and radiotherapy (RT) versus surgery and radiotherapy HR 0.86 (95% CI 0.81, 0.92; p< ) 1. This article was published in The Lancet 375, NSCLC Meta-analysis Collaborative Group, Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data, , Copyright Elsevier 2010; 2. Burdett S, et al., Cochrane Database of Systematic Reviews 2015;2(3):CD Copyright 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5 THE CISPLATIN-BASED ADJUVANT CHEMOTHERAPY META-ANALYSIS +5.4% at 5 yr Pignon JP, et al., J Clin Oncol 2008;26(21): Reprinted with permission. (2008) American Society of Clinical Oncology. All rights reserved.
6 ADJUVANT CHEMOTHERAPY: WHICH STAGES? Overall survival 1 Overall survival 2 curves by stage for the cisplatin-vinorelbine vs. the observation (no chemotherapy) groups 1. Pignon JP, et al., J Clin Oncol 2008; 26(21): Reprinted with permission. (2008), American Society of Clinical Oncology. All rights reserved. 2. Reprinted from J Thorac Oncol 2010; 5, Douillard JY, Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation, , Copyright 2010, with permission from Elsevier.
7 ADJUVANT CHEMOTHERAPY IN STAGE IB NSCLC Interaction p=0.02 Butts CA, et al., J Clin Oncol 2010; 28: Reprinted with permission. (2010) American Society of Clinical Oncology. All rights reserved. Strauss GM, et al., J Clin Oncol 2008; 26(31): Reprinted with permission. (2008) American Society of Clinical Oncology. All rights reserved.
8 ADJUVANT CHEMOTHERAPY: WHICH DRUGS? WHICH DOSES? Pignon JP, J Clin Oncol 2008; 26(21): Reprinted with permission. (2008) American Society of Clinical Oncology. All rights reserved.
9 Log hazard ratio TIMING OF ADJUVANT CHEMOTHERAPY pts US National cancer database Cox proportional hazards model of patients who underwent adjuvant chemotherapy Restricted cubic spine modelling of the relationship between time to initiation of adjuvant chemotherapy and mortality risk 1.0 Covariate No. HR (95% CI) P Value 0.3 Adjuvant chemotherapy timing Reference interval (39-56 d) 5137 [Reference] 0.2 Earlier (<39 d) ( ) Later (>56 d) ( ) propensity-match pairs: HR=0.664 (95%CI: ) p<0.001 >56 days vs. no chemotherapy Days to initiation of adjuvant chemotherapy Salazar MC, et al., JAMA Oncol 2017;3(5):610-9.
10 NEOADJUVANT CHEMOTHERAPY: SURVIVAL RESULTS 1 Individual patient data Meta-analysis NSCLC Meta-analysis Collaborative Group. Lancet 2014;383: NSCLC Meta-analysis Collaborative Group. Open Access article distributed under the terms of CC BY 3.0. Published by Elsevier Ltd.
11 NEOADJUVANT CHEMOTHERAPY: SURVIVAL RESULTS 2 Kaplan-Meier curves (non-stratified) of the effect of preoperative chemotherapy on time to survival 13% reduction in the relative risk of death + 5% at 5 years NSCLC Meta-analysis Collaborative Group. Lancet 2014;383: NSCLC Meta-analysis Collaborative Group. Open Access article distributed under the terms of CC BY 3.0. Published by Elsevier Ltd.
12 WHO SHOULD RECEIVE NEOADJUVANT CHEMOTHERAPY? NSCLC Meta-analysis Collaborative Group. Lancet 2014;383: NSCLC Meta-analysis Collaborative Group. Open Access article distributed under the terms of CC BY 3.0. Published by Elsevier Ltd.
13 ADJUVANT VS. NEOADJUVANT Neo-adjuvant arm (n=97) Chemotherapy (n=97) Surgery (n=82) Eligible Stage IB-IIIA NSCLC (n=214) Randomly assigned (n=198) Adjuvant arm (n=101) Surgery (n=101) Chemotherapy (n=86) Multi-centre phase 3 trial Mar ~ May 2011 Stratification: Gender, centre, stage (IB vs. II vs. IIIA), pathology (adeno vs. non-adeno) Objectives: Primary endpoint: 3-yr DFS Secondary endpoints: safety, 5-yr OS Stop for slow accrual Yang X, et al., J Thoracic Oncol 2017;12(SMA Type 1):S141. Presented at WCLC 2016; 0A09.03.
14 Disease free survival (%) Overall survival (%) ADJUVANT VS. NEOADJUVANT DFS OS Group N Events Median (95%CI) P Adjuvant ( ) Neoadjuvant ( ) Group N Events Median (95%CI) P Adjuvant Neoadjuvant ( ) 100 Hazard ratio (95% CI) = 0.70 ( ) 100 Hazard ratio (95% CI) = 0.71 ( ) Time (years) No. at Risk Adjuvant Neoadj Time (years) No. at Risk Adjuvant Neoadj Yang X, et al., J Thoracic Oncol 2017;12(S1):S141. Presented at WCLC 2016; 0A09.03.
15 ADJUVANT OR NEOADJUVANT CHEMOTHERAPY VS. SURGERY A meta-analysis Reprinted from J Thorac Oncol 2009;4, Lim E, et al., Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non-small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis of Randomized Trials : Copyright 2009, with permission from Elsevier.
16 ADJUVANT OR NEOADJUVANT? Phase III Arm 1: N=212 Surgery 624 patients IA (>2 cm) R Arm 2: N=201 Pacli/Carbo 3 cycles Surgery IB, II, T3N1 Arm 3: N=211 Surgery Pacli/Carbo 3 cycles Paclitaxel 200 mg/m² + carboplatin AUC 6 q3wk Main objective: PFS at 5 yr chemotherapy vs. surgery Felip E, et al., J Clin Oncol 2010; 28:
17 ADJUVANT OR NEOADJUVANT? COMPLIANCE Trials At least 1 cycle 2 cycles 3 cycles 4 cycles ALPI IALT ANITA JBR10 NATCH adj 90% 92% 90% 95.5% 66% ND ND 72% 64% ND 69% ND 61% 55% 61% NA ND 50% 45% NA Depierre NATCH neoadj Gilligan SWOG % 97% 96% ND 90% ND 89% ND NA 90% 96% 79% NA NA NA NA
18 RESPECTIVE ADVANTAGES OF (NEO)ADJUVANT CHEMOTHERAPY Neoadjuvant Adjuvant Level of evidence Staging Earlier delivery Compliance Evaluation of tumour response Research purposes Tissue availability x x x x x x
19 PERIOPERATIVE TREATMENTS IN NSCLC In EGFR wild-type NSCLC Perioperative chemotherapy Preoperative chemoradiation Perioperative targeted treatments Perioperative immunotherapy Postoperative mediastinal radiotherapy In EGFR mutated NSCLC
20 PREOPERATIVE CHEMORADIATION FOR STAGE IIIA N2 Multicentre phase III Pathologically proven stage IIIAN2 1:1 randomisation Cisplatin docetaxel +/- sequential RT (44 Gy / 22 F / 3 wk) Primary endpoint: event-free survival HR=1.1 (95% CI= ); p=0.67 Reprinted from The Lancet, 386, Pless M, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial, Copyright 2015, with permission from Elsevier.
21 PREOPERATIVE CHEMORADIATION FOR STAGE IIIA N2: OVERALL SURVIVAL HR=1 (95% CI= ) Reprinted from The Lancet, 386, Pless M, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial, Copyright 2015, with permission from Elsevier.
22 PERIOPERATIVE TREATMENTS IN NSCLC In EGFR wild-type NSCLC Perioperative chemotherapy Preoperative chemoradiation Perioperative targeted treatments Perioperative immunotherapy Postoperative mediastinal radiotherapy In EGFR mutated NSCLC
23 ADJUVANT GEFITINIB IN ALL-COMERS (BR19) Stage IB, II, IIIA completely resected Trial prematurely closed Gefitinib x 2 yr Goss G, et al. J Clin Oncol 2013; 31: Reprinted with permission (2013) American Society of Clinical Oncology. All rights reserved.
24 ADJUVANT ERLOTINIB IN ALL-COMERS Primary endpoint: DFS Phase III trial Adjuvant erlotinib (2 yr) vs. placebo pstage IB-IIIA OS: HR=1.09 (95%CI= ) p=.815 Kelly K, et al., J Clin Oncol 2015; 33: Reprinted with permission (2015) American Society of Clinical Oncology. All rights reserved.
25 ADJUVANT BEVACIZUMAB *Investigator Choice of 4 chemotherapy regimens 21-day cycles all with Cisplatin given at 75 mg/m 2 on day 1 Cisplatin / Vinorelbine: 30 mg/m 2 day 1, 8 Cisplatin / Docetaxel: 75 mg/m 2 day 1 Cisplatin / Gemcitabine: 1200 mg/m 2 day 1,8 Cisplatin / Pemetrexed: 500 mg/m 2 day 1 (2009 amendment) Bevacizumab 15 mg/kg IV q 3 weeks for up to 1 year Primary endpoint: Overall survival Arm A: Chemotherapy x 4 cycles* ELIGIBLE: STRATIFIED: Resected 1. Cisplatin Doublet* Stage IB (>/= 4cm)-IIIA 2. Stage R 6-12 weeks post-op 3. Histology (AJCC 6 th edition) Arm B: 4. Gender 1:1 Chemotherapy x 4 cycles* + Bevacizumab x 1 year Wakelee H, WCLC 2015: Plen
26 OS probability DFS probability ADJUVANT BEVACIZUMAB OS DFS 1.0 OS hazard ratio (B:A): % CI: p= DFS hazard ratio (B:A): % CI: p= Chemo (208 events/749 cases) Chemo + bevacizumab (204 events/752 cases) Chemo (338 events/749 cases) Chemo + bevacizumab (334 events/752 cases) Months from registration Months from registration Wakelee H, et al., Presented at WCLC 2015: Plen With permission from Professor Heather Wakelee.
27 PERIOPERATIVE TREATMENTS IN NSCLC In EGFR wild-type NSCLC Perioperative chemotherapy Preoperative chemoradiation Perioperative targeted treatments Perioperative immunotherapy Postoperative mediastinal radiotherapy In EGFR mutated NSCLC
28 MAGE A-3 VACCINE IN MAGE A-3+ NSCLC: DFS Resected stage I, II, IIIA NSCLC - 13 intramuscular injections in 27 months - Primary endpoint: DFS Reprinted from The Lancet Oncology, 17, Vansteenkiste JF, et al., Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial; Copyright 2016, with permission from Elsevier.
29 MAGE A-3 VACCINE IN MAGE A-3+ NSCLC: OVERALL SURVIVAL Reprinted from The Lancet Oncology, 17, Vansteenkiste JF, et al., Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial; Copyright 2016, with permission from Elsevier.
30 NEOADJUVANT NIVOLUMAB 18 pts with resectable stage I IIIA NSCLC Nivolumab 3 mg/kg D-28&14, prior to surgery Responses: 7 major pathologic response (<10% residual tumour) 1 complete pathologic response 13 stable disease 1 Grade 3 4 adverse event No delay in surgery in any patient Increased T cell infiltrate in responders Forde P, ESMO 2016: Abstract LBA41_PR
31 ONGOING PHASE III TRIALS OF ADJUVANT CHECKPOINT INHIBITORS Drug (trial) Control Stages PD-L1 Primary endpoint Nivolumab (ALCHEMIST/ANVL US NCI) Atezolizumab (Impower 010) MEDI 4736 (international) Pembrolizumab (Keynote 091 EORTC/ETOP) observation placebo placebo placebo IB (4 cm) IIIA, after adjuvant chemo and/or radiotherapy IB (4 cm) IIIA, after adjuvant chemo IB (4 cm) IIIA, after adjuvant chemo IB (4 cm) IIIA, after adjuvant chemo all all all all OS/DFS DFS DFS DFS
32 PERIOPERATIVE TREATMENTS IN NSCLC In EGFR wild-type NSCLC Perioperative chemotherapy Preoperative chemoradiation Perioperative targeted treatments Perioperative immunotherapy Postoperative mediastinal radiotherapy In EGFR mutated NSCLC
33 POSTOPERATIVE RADIOTHERAPY Reprinted from Int. J. Radiation Oncology Biol. Phys., 2008; 72, Douillard JY, et al., Impact of Postoperative Radiation Therapy on Survival in Patients with Complete Resection and Stage I, II, or IIIA Non-Small-Cell Lung Cancer treated with Adjuvant Chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial, Copyright 2008, with permission from Elsevier.
34 POSTOPERATIVE RADIOTHERAPY: THE UPDATED META-ANALYSIS IPD meta-analysis 11 trials / 2343 pts HR= % relative increase in risk of death Absolute detriment: 5% at 2 yr (95% CI=2-9%) Reducing survival from 58 to 53% Burdett S, et al., Cochrane Database Syst Rev. 2016;10:CD Copyright 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
35 POSTOPERATIVE RADIOTHERAPY FOR STAGE III? FOR N2? Postoperative radiotherapy may be detrimental in earlier stages Burdett S, et al., Cochrane Database Syst Rev. 2016;10:CD Copyright 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
36 LUNG ART IFCT05-03 Complete resection Pathological N2 Eligible: Pre and/or postoperative chemotherapy accepted Primary endpoint: Disease-free survival 433/500 pts included R 1:1 Arm A: Control Arm B: Conformational radiotherapy (54 Gy)
37 PERIOPERATIVE TREATMENTS IN NSCLC In EGFR wild-type NSCLC Perioperative chemotherapy Preoperative chemoradiation Perioperative targeted treatments Perioperative immunotherapy Postoperative mediastinal radiotherapy In EGFR mutated NSCLC
38 ERLOTINIB IN EGFR-MUT IN RADIANT NS due to hierarchical testing OS immature Kelly K, et al., J Clin Oncol 2015; 33: Reprinted with permission 2015 American Society of Clinicl Oncology. All rights reserved.
39 ONGOING EGFR TKI ADJUVANT TRIALS IN EGFR-MUT PATIENTS Trial Country EGFR TKI Control EGFR TKI duration ALCHEMIST USA Erlotinib Crizotinib (for ALK+) Placebo IMPACT WJOG 6401L Japan gefitinib Cisplatin vinorelbine x4 C-TONG 1104 China gefitinib Cisplatin vinorelbine x4 NCT without adjuvant chemo NCT (after 4 cycles of adjuvant platinum-based chemo) 2 yr 2 yr 2 yr China Icotinib Placebo 6-12 months China Icotinib observation 6-12 months
40 CONCLUSIONS: PERIOPERATIVE CHEMOTHERAPY Neoadjuvant and adjuvant chemotherapy increase survival in resectable NSCLC: Comparable effectiveness of +5% at 5 years Adjuvant chemotherapy: Stage II-III, IB 4 cm Best evidence for cisplatin-vinorelbine Cisplatin 300 mg/m 2
41 CONCLUSIONS: PERIOPERATIVE RADIOTHERAPY Preoperative radiotherapy does not add to preoperative chemotherapy in stage IIIA N2 Postoperative radiotherapy can be delivered in pn2 disease
42 CONCLUSIONS: NEW TREATMENTS No indication for targeted therapies in wild-type EGFR Activity of EGFR and ALK TKIs to be demonstrated in EGFRmut/ALK+ NSCLC Activity of immune checkpoint inhibitors to be demonstrated
43 THANK YOU!
Is the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationSystemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationState of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy?
ESMO Preceptorship Programme NSCLC Singapore 13 14 dec 2016 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationAdjuvant Therapy in NSCLC. Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia
Adjuvant Therapy in NSCLC Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia Agenda What do we expect today from new adjuvant chemotherapy Which data do we have with targeted agents
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationSystemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationDebate on stage III NSCLC: The role of systemic therapy
1 Debate on stage III NSCLC: The role of systemic therapy Rolf Stahel University Hospital of Zürich Bucharest, 16.6..2015 2 Stage III disease: The problem of heterogeneity, the risk of distant metastases
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationAdjuvant radiotherapy for completely resected early stage NSCLC
Adjuvant radiotherapy for completely resected early stage NSCLC ESMO Preceptorship on lung Cancer Manchester March 2018 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationOptimal Application of Adjuvant Therapy in NSCLC
Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial Stage n Chemo
More informationSlide 1. Slide 2 Post 1995 Meta-Analysis : Slide 3
Slide 1 Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Slide 2 Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationAdjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine
Editorial Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine Peng Shen 1, Wenzhao Zhong 2 1 Department of Oncology, Nanfang Hospital, Southern Medical
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationThe 5-year survival in patients with resected NSCLC ranges
SHIRISH M. GADGEEL Role of Chemotherapy and Targeted Therapy in Early-Stage Non Small Cell Lung Cancer Shirish M. Gadgeel, MD OVERVIEW On the basis of several randomized trials and meta-analyses, adjuvant
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationNSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy
Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local
More informationLung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000
More informationAdjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?
Editorial Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough? Giandomenico Roviello 1, Marco Imperatori 1, Michele Aieta 1, Francesco Sollitto 2, Matteo Landriscina
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationAdjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer
Review Article Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer Robert Pirker Department of Medicine I, Medical University of Vienna, Vienna, Austria Correspondence
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationAdjuvant Therapies for Lung Cancers: New Directions
Adjuvant Therapies for Lung Cancers: New Directions Mark G Kris, MD Member and Attending Physician William and Joy Ruane Chair in Thoracic Oncology Memorial Sloan-Kettering Professor of Medicine, Weill
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationImmunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss
More informationENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationThe Evolving Role of Adjuvant Therapies
Therapy-predictive markers for adjuvant chemotherapy The Evolving Role of Adjuvant Therapies Micrometastasis Prognostic Markers (BRCA1) Cured No Further Tx Chemosensitive Rafael Rosell th European Perspectives
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019 DISCLAIMER Not a Substitute for Professional Advice
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationCooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D.
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology Group (JCOG) Chief, Division of Thoracic Surgery, Kanagawa
More informationNEJ, Sendai North East Japan. TCOG, Tokyo Tokyo Clinical Oncology G.
Slide 1 Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology Group (JCOG) Chief, Division of Thoracic Surgery,
More informationRuolo emergente dell immunoterapia nello stadio III. Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy)
Ruolo emergente dell immunoterapia nello stadio III Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy) Disclosures Advisory Boards / Honoraria / Speakers fee / Consultant for: MSD,
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationNeo-adjuvant chemotherapy in NSCLC
SCLC Epidemiology eo-adjuvant chemotherapy in SCLC Sarita Dubey sst Professor, Medical ncology, UCSF UCSF/UC Davis Thoracic conference ovember 8, 2008 Statistics for 2008 Cancer Incidence Deaths Colon
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
More informationStage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Introduction 1/3 of the total lung cancer cases few patients are cured with single modality
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationCooperative Group Update - Japan; JCOG & WJOG -
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationCHEMIOTERAPIA ADIUVANTE NEL NSCLC Dr. RITA CHIARI Oncologia Medica - Perugia.
! CHEMIOTERAPIA ADIUVANTE NEL NSCLC Dr. RITA CHIARI Oncologia Medica - Perugia ritachiar@gmail.com ! DICHIARAZIONE Relatore: RITA CHIARI Come da nuova regolamentazione della Commissione Nazionale per la
More informationPrognostic and predictive biomarkers in
OLOGICAL SCIENCES O DEPT. OF CLINICAL & BIO UNIVERSITY UNIVERSTY OF TORINO Prognostic and predictive biomarkers in early stage NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical &
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationERCC-1 1 and response to chemotherapy. Jean-Charles SORIA, MD, PhD Institut Gustave Roussy
ERCC-1 1 and response to chemotherapy 1 Jean-Charles SORIA, MD, PhD Institut Gustave Roussy Cancer and Chemotherapy: the exemple of Lung Cancer 2 50 CT + supportive care 40 Surgery ± CT Patients (%) 30
More informationREPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group OUR 10 MESSAGE HIGHLIGHTS 1/ Advanced NSCLC 1 st line: IO
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More information